Naseem Zojwalla - 19 Dec 2025 Form 4 Insider Report for Olema Pharmaceuticals, Inc. (OLMA)

Role
Chief Medical Officer
Signature
/s/ Shane Kovacs, Attorney-in-Fact
Issuer symbol
OLMA
Transactions as of
19 Dec 2025
Net transactions value
-$5,865,756
Form type
4
Filing time
23 Dec 2025, 21:40:55 UTC
Previous filing
03 Mar 2025
Next filing
04 Feb 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Zojwalla Naseem Chief Medical Officer C/O OLEMA PHARMACEUTICALS, INC., 780 BRANNAN STREET, SAN FRANCISCO /s/ Shane Kovacs, Attorney-in-Fact 23 Dec 2025 0001905871

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction OLMA Common Stock Options Exercise $610,000 +40,000 +30% $15.25 173,997 19 Dec 2025 Direct F1
transaction OLMA Common Stock Sale $1,599,924 -57,079 -33% $28.03 116,918 19 Dec 2025 Direct F2
transaction OLMA Common Stock Sale $373,805 -12,921 -11% $28.93 103,997 19 Dec 2025 Direct F3
transaction OLMA Common Stock Options Exercise $652,974 +42,818 +41% $15.25 146,815 22 Dec 2025 Direct
transaction OLMA Common Stock Options Exercise $50,418 +7,182 +4.9% $7.02 153,997 22 Dec 2025 Direct
transaction OLMA Common Stock Sale $2,804,000 -100,000 -65% $28.04 53,997 22 Dec 2025 Direct F4
transaction OLMA Common Stock Options Exercise $351,000 +50,000 +93% $7.02 103,997 23 Dec 2025 Direct
transaction OLMA Common Stock Sale $2,752,419 -99,509 -96% $27.66 4,488 23 Dec 2025 Direct F5

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction OLMA Stock Option (Right to Buy) Options Exercise $0 -40,000 -21% $0.000000 155,000 19 Dec 2025 Common Stock 40,000 $15.25 Direct F6
transaction OLMA Stock Option (Right to Buy) Options Exercise $0 -42,818 -28% $0.000000 112,182 22 Dec 2025 Common Stock 42,818 $15.25 Direct F6
transaction OLMA Stock Option (Right to Buy) Options Exercise $0 -7,182 -3.4% $0.000000 206,818 22 Dec 2025 Common Stock 7,182 $7.02 Direct F7
transaction OLMA Stock Option (Right to Buy) Options Exercise $0 -50,000 -24% $0.000000 156,818 23 Dec 2025 Common Stock 50,000 $7.02 Direct F7
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Includes 4,488 shares acquired under the Issuer's Employee Stock Purchase Plan on June 30, 2025.
F2 The weighted average sale price for the transaction reported was $28.03, and the range of prices was between $27.50 and $28.49. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided.
F3 The weighted average sale price for the transaction reported was $28.93, and the range of prices was between $28.51 and $29.44. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided.
F4 The weighted average sale price for the transaction reported was $28.04, and the range of prices was between $27.655 and $28.36. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided.
F5 The weighted average sale price for the transaction reported was $27.66, and the range of prices was between $27.50 and $27.83. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided.
F6 25% of the shares subject to the option vest on February 1, 2025 and 1/48 of the total number of shares subject to the option vest each month thereafter, subject to the Reporting Person's continuous service through each applicable vesting date.
F7 25% of the shares subject to the option vested on January 31, 2023 and 1/48 of the total number of shares subject to the option vest each month thereafter, subject to the Reporting Person's continuous service through each applicable vesting date.